The Matthew Larson Foundation For Pediatric Brain Tumors – Trademark Portfolio
Entity Type: 99
The Matthew Larson Foundation For Pediatric Brain Tumors holds 5 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 36 (Insurance & Financial) — 5 filings in this category. Currently, 3 trademarks are registered. Notable registered marks include IRONKIDS and IRONMATT. The owner is based in Franklin Lakes, NJ.
965 Lily Pond Lane
Franklin Lakes, NJ 07417
Showing of trademarks Trademarks
Trademark Classifications
The Matthew Larson Foundation For Pediatric Brain Tumors's trademark portfolio spans 1 Nice Classification class, reflecting the scope of goods and services protected under their brand portfolio.
Insurance; financial affairs; monetary affairs; real estate affairs
Frequently Asked Questions
How many trademarks does The Matthew Larson Foundation For Pediatric Brain Tumors have?
The Matthew Larson Foundation For Pediatric Brain Tumors has 5 U.S. trademarks filed with the USPTO. Of these, 3 registered, 2 cancelled.
What trademark classes does The Matthew Larson Foundation For Pediatric Brain Tumors file in?
The Matthew Larson Foundation For Pediatric Brain Tumors files trademarks across 1 Nice Classification class. The most active classes are Class 36 (Insurance & Financial). Class 36 covers insurance; financial affairs; monetary affairs; real estate affairs.
What are The Matthew Larson Foundation For Pediatric Brain Tumors's most well-known trademarks?
The Matthew Larson Foundation For Pediatric Brain Tumors's registered trademark portfolio includes well-known marks such as IRONKIDS and IRONMATT. These are among 3 currently registered trademarks in the portfolio.
What is The Matthew Larson Foundation For Pediatric Brain Tumors's trademark registration success rate?
The Matthew Larson Foundation For Pediatric Brain Tumors has a 60% trademark registration rate, with 3 out of 5 resolved applications resulting in successful registration. Currently, 0 applications are pending review.